Marinus Pharmaceuticals, Inc. (MRNS): Price and Financial Metrics


Marinus Pharmaceuticals, Inc. (MRNS): $5.66

0.80 (+16.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRNS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MRNS POWR Grades


  • Sentiment is the dimension where MRNS ranks best; there it ranks ahead of 57.8% of US stocks.
  • MRNS's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
  • MRNS ranks lowest in Momentum; there it ranks in the 12th percentile.

MRNS Stock Summary

  • With a price/sales ratio of 24.07, Marinus Pharmaceuticals Inc has a higher such ratio than 93.8% of stocks in our set.
  • With a year-over-year growth in debt of 272%, Marinus Pharmaceuticals Inc's debt growth rate surpasses 95.61% of about US stocks.
  • Revenue growth over the past 12 months for Marinus Pharmaceuticals Inc comes in at 793.19%, a number that bests 98.77% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Marinus Pharmaceuticals Inc are BCDA, ADAP, DCPH, MIST, and MIRM.
  • Visit MRNS's SEC page to see the company's official filings. To visit the company's web site, go to www.marinuspharma.com.

MRNS Valuation Summary

  • In comparison to the median Healthcare stock, MRNS's EV/EBIT ratio is 114.33% lower, now standing at -4.2.
  • MRNS's price/sales ratio has moved up 0.3 over the prior 86 months.
  • MRNS's EV/EBIT ratio has moved up 6.7 over the prior 86 months.

Below are key valuation metrics over time for MRNS.

Stock Date P/S P/B P/E EV/EBIT
MRNS 2021-08-31 NA 4.8 -5.4 -4.2
MRNS 2021-08-30 NA 4.7 -5.3 -4.1
MRNS 2021-08-27 NA 4.8 -5.4 -4.2
MRNS 2021-08-26 NA 4.6 -5.2 -4.1
MRNS 2021-08-25 NA 4.7 -5.3 -4.1
MRNS 2021-08-24 NA 4.7 -5.3 -4.1

MRNS Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at -49.86%.
  • Its 2 year price growth rate is now at -62.03%.
  • The 3 year net income to common stockholders growth rate now stands at -72.39%.
Over the past 34 months, MRNS's revenue has gone up $15,345,000.

The table below shows MRNS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 15.345 -55.477 -98.776
2021-09-30 15.372 -50.125 -87.94
2021-06-30 5.429 -69.997 -84.092
2021-03-31 3.524 -63.05 -75.944
2020-12-31 1.718 -60.912 -76.355
2020-09-30 0.171 -60.763 -74.295

MRNS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRNS has a Quality Grade of D, ranking ahead of 11.62% of graded US stocks.
  • MRNS's asset turnover comes in at 0 -- ranking 440th of 682 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with MRNS.

The table below shows MRNS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -66.832
2021-03-31 0 NA -93.470
2020-12-31 0 NA -20.937
2020-09-30 0 NA -22.684
2020-06-30 0 NA -28.712
2020-03-31 0 NA -57.851

MRNS Price Target

For more insight on analysts targets of MRNS, see our MRNS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.88 Average Broker Recommendation 1.25 (Strong Buy)

MRNS Stock Price Chart Interactive Chart >

Price chart for MRNS

MRNS Price/Volume Stats

Current price $5.66 52-week high $19.83
Prev. close $4.86 52-week low $4.19
Day low $5.05 Volume 357,900
Day high $5.80 Avg. volume 311,134
50-day MA $7.86 Dividend yield N/A
200-day MA $10.57 Market Cap 209.50M

Marinus Pharmaceuticals, Inc. (MRNS) Company Bio


Marinus Pharmaceuticals is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The company was founded in 2003 and is based in Radnor, Pennsylvania.


MRNS Latest News Stream


Event/Time News Detail
Loading, please wait...

MRNS Latest Social Stream


Loading social stream, please wait...

View Full MRNS Social Stream

Latest MRNS News From Around the Web

Below are the latest news stories about Marinus Pharmaceuticals Inc that investors may wish to consider to help them evaluate MRNS as an investment opportunity.

Marinus slips to a 52-week low as analysts react to delays for clinical studies

Marinus (MRNS -20.5%) has recorded the biggest intraday loss since March 2020 on Wednesday to approach a 52-week low after the clinical-stage pharma company announced delays for several clinical programs involving an IV formulation of its only product candidate, ganaxolone. The company attributed the setback to COVID-19 impact on enrollment and...

Seeking Alpha | February 23, 2022

Marinus Pharma Delays Status Epilepticus, IV Ganaxolone Clinical Trials Into 2023

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) expects data from the RAISE Phase 3 trial of ganaxolone in refractory status epilepticus in 2H of 2023. Earlier data from the trial was expected in 2H of 2022. The delay is due to the impact of the COVID-19 omicron variant and an interruption of clinical supply material associated with IV ganaxolone. Marinus has temporarily paused the RAISE trial after routine monitoring of stability batches of clinical supply material indicated that it became necessary

Yahoo | February 23, 2022

Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

RADNOR, Pa., February 22, 2022--Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

Yahoo | February 22, 2022

Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022

RADNOR, Pa., February 16, 2022--Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022

Yahoo | February 16, 2022

Is Marinus Pharmaceuticals (NASDAQ:MRNS) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | February 14, 2022

Read More 'MRNS' Stories Here

MRNS Price Returns

1-mo N/A
3-mo -52.83%
6-mo -54.02%
1-year -65.02%
3-year -68.56%
5-year 13.20%
YTD -52.36%
2021 -2.62%
2020 41.20%
2019 -24.74%
2018 -64.83%
2017 707.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7014 seconds.